Vascularized Islet Transplantation as Composite Islet-Kidney Grafts with Nanoparticle-Labeled Islets in Large Animal Preclinical Transplant Models.
Level 5 - mechanism / opinion, no new human data
Preclinical animal model methodology paper with no human clinical data.
PubMed 36507998 · doi:10.1007/978-1-0716-2807-2_17
What was done
The authors describe a preclinical living-donor transplantation protocol in large-animal models to address diabetic nephropathy. The strategy involves transplanting donor islets under the donor's own renal capsule for autologous prevascularization and utilizing an siRNA-nanoparticle probe to minimize required pancreatic resection size prior to transplanting the composite islet-kidney graft into a recipient.
What was found
The abstract reports that autologous prevascularization preserved islets, reduced ischemic loss compared to standard intraportal administration, provided renal-mediated immunoprotection, and achieved normal glycemic control in diabetic preclinical models with limited pancreas resection. The abstract reports no quantitative values or sample sizes.
Why it matters
If successfully translated, this composite grafting approach could overcome key barriers in live-donor islet transplantation—namely severe ischemic islet loss and graft rejection—by reducing the volume of donor pancreatic tissue required for glycemic control.
Limits
The abstract describes a preclinical protocol in large animals with no sample sizes, control comparisons, quantitative outcomes, or statistical data reported. Findings are preclinical and cannot establish clinical efficacy or safety in humans.